Q2 2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: R&G Pharma(301333) the Revenue is 249.87 M (+20.81%);the EBIT is 32 M (-5.56%);the EPS is 0.22 (-40.64%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.25B20.81%
----
----
EBIT
0.03B5.56%
----
----
EPS
0.220340.64%
----
----
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf